PVI
RCKT icon

Pura Vida Investments’s Rocket Pharmaceuticals RCKT Stock Holding History

Pura Vida Investments’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-150,000
Closed -$2.94M – 150
2022
Q4 		$2.94M Buy
+150,000
New +$2.76M 0.15% 108

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Pura Vida Investments's RCKT Position: Q4 2022 in Review

Pura Vida Investments sold out of Rocket Pharmaceuticals (RCKT) in Q4 2022, closing a stake of 50,000 shares — an estimated $921K sold.

Pura Vida Investments first reported a position in RCKT in Q1 2015 and held it in 10 quarters. The position peaked at $2.48M in Q4 2019. 168 funds tracked by Wall St. Rank hold RCKT as of Q4 2022.

  • Pura Vida Investments reported no remaining Rocket Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Pura Vida Investments sold 50,000 Rocket Pharmaceuticals shares in Q4 2022, an estimated $921K.
  • Pura Vida Investments first reported a position in Rocket Pharmaceuticals in Q1 2015 and held it in 10 quarters.
  • Pura Vida Investments's Rocket Pharmaceuticals position peaked at $2.48M in Q4 2019.
  • 168 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2022.

Based on Pura Vida Investments's 13F filing for Q4 2022, filed 14 Feb 2023.